Form 4: Shawn Tomasello, 4D Molecular Therapeutics Director, Acquires 22,500 Stock Options

Director Shawn Tomasello acquired 22,500 stock options in 4D Molecular Therapeutics on May 21, 2024, according to a recent SEC filing.

Summary

• Shawn Tomasello, a director of 4D Molecular Therapeutics, acquired 22,500 stock options on May 21, 2024.
• The options were automatically granted as part of the company's non-employee director compensation program.
• The exercise price of the stock options is $25.15.
• The options vest in three tranches: 1/3 on May 21, 2025, and then in equal monthly installments until fully vested on May 21, 2027, contingent upon continued service.
• The stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of a stock option grant, which is neither particularly positive nor negative on its own. The vesting schedule is typical and aligns with industry practices.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.
• The vesting schedule incentivizes the director to remain with the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

This filing is a routine disclosure of insider transactions, common in the biopharmaceutical industry where stock options are frequently used as part of executive compensation packages to align management's interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation for directors in publicly traded biotechnology companies.
• Companies like CRISPR Therapeutics and Beam Therapeutics also utilize stock options extensively in their director compensation packages.
• The vesting schedule described is typical, designed to incentivize long-term commitment and performance.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates